The Importance of TIMI 3 flow in primary angioplasty

Original title: Predicitors of suboptimal TIMI flow alter primary angioplasty for acute myocardial infarction: results from the HORIZON-AMI trial. Reference: Adriano Caixeta et al.  Eurointervention 2013;9:220-227

Primary angioplasty showed greater efficacy than thrombolytics but one out of every four patients cannot achieve TIMI 3 flow.

The Horizons-AMI trial randomized 3,602 patients to receive bivalirudin or heparin plus inhibitors IIb IIIa and after angiography a second randomization took place to DES or a conventional stent. The primary objective of this analysis was to evaluate the angiographic predictors of both clinical and suboptimal procedural flow (TIMI <3) after stent implantation. The secondary objective was the impact after three years of suboptimal flow, (TIMI 0-2 versus TIMI 3). Angioplasty was performed in 3,345 patients, (92.9%), of which 2,758, (87.1%), had final TIMI 3 flow.

Those who had TIMI

After 30 days and three years, end TIMI flow

Conclusion:

In this large study the lack of restoration of TIMI 3 flow was associated with older age, past infarction, TIMI flow 0-1, lesion length and was a strong predictor of mortality.

Commentary:

This study shows that the failure to achieve TIMI 3 is associated with higher mortality at three years, than the PAMI, Cadillac and Apex IMA studies had shown at six months. It may be important to have a good pre-hospital service where trained personnel are available to bypass the emergency department and refer the patient directly to the catheterization laboratory. 

Courtesy of Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation.
Buenos Aires, Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...